Leerink Partnrs Weighs in on Pfizer’s Q4 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Equities researchers at Leerink Partnrs dropped their Q4 2024 earnings estimates for shares of Pfizer in a note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $0.62 per share for the quarter, down from their prior estimate of $0.63. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer’s Q2 2025 earnings at $0.55 EPS and Q4 2025 earnings at $0.64 EPS.

PFE has been the subject of several other research reports. Guggenheim decreased their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup started coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday. One analyst has rated the stock with a sell rating, nine have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $32.43.

Pfizer Stock Performance

Shares of PFE opened at $25.58 on Thursday. Pfizer has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock’s fifty day moving average price is $27.23 and its two-hundred day moving average price is $28.29. The firm has a market cap of $144.96 billion, a PE ratio of 34.38, a PEG ratio of 0.63 and a beta of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same quarter last year, the business posted ($0.17) EPS. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year.

Institutional Trading of Pfizer

Several hedge funds and other institutional investors have recently bought and sold shares of PFE. State Street Corp boosted its stake in shares of Pfizer by 1.2% in the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company’s stock valued at $8,405,930,000 after purchasing an additional 3,405,539 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after buying an additional 12,864,343 shares during the period. Geode Capital Management LLC grew its stake in shares of Pfizer by 1.6% during the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock valued at $3,392,342,000 after buying an additional 1,855,419 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Pfizer by 3.2% in the second quarter. Massachusetts Financial Services Co. MA now owns 71,794,056 shares of the biopharmaceutical company’s stock worth $2,008,798,000 after buying an additional 2,241,609 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after acquiring an additional 6,977,587 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity

In other news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.72%. Pfizer’s dividend payout ratio is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.